AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05084261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT051 200 mg
Description: Oral BT051 200 mg once daily for 28 days.
Study NCT05084261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT051 800 mg
Description: Oral BT051 800 mg once daily for 28 days.
Study NCT05084261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT051 3200 mg
Description: Oral BT051 3200 mg once daily for 28 days.
Study NCT05084261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo Matching BT051
Study NCT04378634 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Sub-maximal exercise test
Study NCT04378634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Sub-maximal exercise test
Study NCT04378634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mental Stress Test
Description: Computerised mental arithmetic challenges and social evaluative threat tasks
Study NCT04378634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Stress Test
Description: Computerised mental arithmetic challenges and social evaluative threat tasks
Study NCT05756556 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: T3011 + Cobimetinib
Description: 1e8 plaque-forming units (PFU)/mL (up to 10 mL, every 2 weeks \[Q2W\], 28 days/cycle) T3011 will be administered in combination with 60 mg Cobimetinib (once daily \[QD\] for the first 21 days of each 28-day cycle)
Study NCT06110143 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Periodontal treatment
Description: Periodontal treatment
Study NCT05031936 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cervical spinal injection with 0.2% ropivacaine
Description: spinal injections performed in cervical pillar area to relieve chronic neck pain
Study NCT05031936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical spinal injection with 0.2% ropivacaine
Description: spinal injections performed in cervical pillar area to relieve chronic neck pain
Study NCT06251726 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunoscore Colon Test
Description: Immunoscore Colon is an in-vitro diagnostic test, allowing the quantification of CD3 and CD8 positive cells in formalin-fixed paraffin-embedded (FFPE) tissue samples of primary colon cancer.~The test uses immunohistochemistry, digital pathology techniques and a dedicated image analysis software to determine CD3+ and CD8 + cell densities in the tumor ant in the invasive margin of the tumor.
Study NCT05926856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine green
Description: Indocyanine Green 25mg kit for injection
Study NCT05926856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Indocyanine Green 25mg kit for injection
Study NCT06781983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH4502
Description: Part 1 (dose escalation) and Part 2 (dose optimization)
Study NCT05742724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol-Cannabidiol Combination
Description: Oral THC 0.1mg/kg and CBD 2.5mg/kg
Study NCT04990310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-CORT113176
Description: \[14C\]-CORT113176 450 mg lipid formulation capsule for oral administration containing not more than 3.37 megaBequerel 14C.
Study NCT06268353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: Measure CAPGDF15 in plasma of 3 pregnant and 3 non-pregnant women
Study NCT05990920 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK02
Description: SNK02 is ex vivo expanded allogeneic NK cells for IV injection, is a light-yellow cryopreserved cell suspension consisting of NK cells isolated from healthy donor's peripheral blood mononuclear cells.
Study NCT02127684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: ranibizumab 0.3mg intravitreally monthly
Study NCT02127684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: ranibizumab given every 2 weeks for 8 weeks then monthly as needed
Study NCT05631574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMF-219
Description: BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
Study NCT06781931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DG1 Spectacle Lens
Description: DG1 spectacle lens, daily wear for 36 months
Study NCT06781931 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Single Vision Spectacle Lens
Description: Single vision spectacle lens, daily wear for 36 months
Study NCT06780410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempedoic Acid Tablet
Description: Once daily, oral
Study NCT06780410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, oral
Study NCT06040892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SPHERE protocol : Spatial hearing performances test
Description: Participants will be instructed to localize a sound emitted in their environment using a virtual reality setup (SPHERE protocol).
Study NCT06040892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: SPHERE protocol : Spatial hearing performances test
Description: Participants will be instructed to localize a sound emitted in their environment using a virtual reality setup (SPHERE protocol).
Study NCT06040892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FRASIMAT Test : audiology test of speech in noise perception
Description: Intelligibility threshold is the signal-to-noise ratio (in decibels) for which the subject can repeat 50% of the words heard in a dichotic listening.
Study NCT06040892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FRASIMAT Test : audiology test of speech in noise perception
Description: Intelligibility threshold is the signal-to-noise ratio (in decibels) for which the subject can repeat 50% of the words heard in a dichotic listening.
Study NCT06040892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Kid SSQ questionnaire of life : The Speech, Spatial and Other Qualities of Hearing Scale
Description: The SSQ questionnaire is a clinical subjective scale that allows evaluating of hearing performances in daily life. The questionnaire is divided into 3 main items (A: speech; B: spatial hearing; C: other qualities of hearing) comprising questions with rating scores out of ten.
Study NCT06040892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Kid SSQ questionnaire of life : The Speech, Spatial and Other Qualities of Hearing Scale
Description: The SSQ questionnaire is a clinical subjective scale that allows evaluating of hearing performances in daily life. The questionnaire is divided into 3 main items (A: speech; B: spatial hearing; C: other qualities of hearing) comprising questions with rating scores out of ten.
Study NCT06040892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spatial hearing rehabilitation program
Description: The tool makes it possible to propose rehabilitation programs adapted to the performance and expectations of each child. This program will manipulate both the ambient sound with varying background noise to simulate daily life environments (i.e. making auditory detection more or less complex), and also manipulate virtual immersive environment (i.e. giving more or less relevant visual cues related to real sound location).
Study NCT04699188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: KRAS G12C inhibitor
Study NCT04699188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: SHP2 inhibitor
Study NCT04699188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: Anti PD1 antibody
Study NCT05541861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Study NCT05541861 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Study NCT05541861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b4 5 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Study NCT05541861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b4 10 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Study NCT05541861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b4 15 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Study NCT05541861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b4 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Study NCT05541861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Study NCT04746430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms
Study NCT06667336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intermittent suction
Description: This suction was applied only as needed to clear secretions
Study NCT06667336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous suction
Description: The suction catheter was inserted at the start of laryngoscopy and maintained in the oropharynx until the moment of ETT delivery.
Study NCT06667557 — intervention group
Intervention type: DEVICE
Intervention: Superpulse Thulium Fiber Laser (sTFL) Treatment
Description: The superpulse thulium fiber laser (sTFL) was used as a minimally invasive surgical treatment for kidney and upper ureteral stones. All procedures were performed by experienced urologists using standard techniques for laser lithotripsy. Laser settings, such as pulse energy and frequency, were adjusted according to stone characteristics and the surgeon's judgment to optimize treatment efficacy and safety.
Study NCT06667557 — intervention group
Intervention type: DEVICE
Intervention: Holmium:YAG Laser (Ho:YAG) Treatment
Description: The holmium:YAG laser (Ho:YAG) was used as a minimally invasive surgical treatment for kidney and upper ureteral stones. All procedures were performed by experienced urologists using standard techniques for laser lithotripsy. Laser settings, such as pulse energy and frequency, were adjusted according to stone characteristics and the surgeon's judgment to optimize treatment efficacy and safety.
Study NCT06671522 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: It is a qualitatative research. Only a survey.
Study NCT06671418 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary percutaneous stenting (PPS)
Description: PPS bridging malignant hilar biliary obstruction with self-expandable uncovered metal stents without crossing the ampulla and without leaving an external drain. The procedure is performed by an interventional radiologist who has performed at least 5 PPS procedures.
Study NCT06671418 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic biliary drainage
Description: EBD according to the American Society for Gastrointestinal Endoscopy (ASGE) guidelines of 2021. The procedure is performed by a gastro-enterologist who is experienced in performing EBD in patients with a MHBO.
Study NCT06671951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focal Vibration
Description: Focal vibration is a 3x3 electrode placed on the athlete's muscle belly, and emits a high frequency vibration (150Hz) to stimulate the muscle spindle and generate greater muscle activation.
Study NCT06671951 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham focal vibration
Description: Is a focal vibration intervention but without conctact in the athelte's skin. Doing this we got a sham therapy
Study NCT06671197 — intervention group
Intervention type: DEVICE
Intervention: Pulmonary vein isolation
Description: Pulsed field ablation
Study NCT06671197 — intervention group
Intervention type: DEVICE
Intervention: Pulmonary vein isolation+posterior left atrial wall line
Description: Pulsed field ablation
Study NCT06671197 — intervention group
Intervention type: DEVICE
Intervention: Pulmonary vein isolation+posterior left atrial wall line+superior vena cava isolation
Description: Pulsed field ablation
Study NCT06672367 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balance training group
Description: It includes participants receiving balance training for mild cognitive impairment.~Balance training~Walking on a flat surface at the beginning of each session for 5-10 minutes Perform different static and dynamic balance exercises along with cognitive tasks.~Static standing with feet together with eyes open and closed Semi-tandem stand and tandem stand Forward and backward weight shift exercises Counting backwards by threes, Naming object or animals, Recalling a short sequence of numbers or words.~Side stepping, marching, forward and backward walking Hip extension and abduction Cognitive task includes word association or simple math problems. Standing on one leg Relaxation and breathing exercises including deep inhaling and exhaling or walking slowly at the end of each session for 5-10 minutes During training sessions, balance activities and cognitive tasks will be implemented simultaneously.
Study NCT06672367 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balance training combined with gaze stability exercises
Description: It includes participants receiving balance training combined with gaze stability exercises for mild cognitive impairment.~Balance training~Walking on a flat surface at the beginning of each session for 5-10 minutes Perform different static and dynamic balance exercises along with cognitive tasks.~Static standing with feet together with eyes open and closed Semi-tandem stand and tandem stand Forward and backward weight shift exercises Counting backwards by threes, Naming object or animals, Recalling a short sequence of numbers or words.~Side stepping, marching, forward and backward walking Hip extension and abduction Cognitive task includes word association or simple math problems. Standing on one leg Relaxation and breathing exercises including deep inhaling and exhaling or walking slowly at the end of each session for 5-10 minutes During training sessions, balance activities and cognitive tasks will be implemented simultaneously.~Gaze stability exercises~Visual tracking exercises
Study NCT06671769 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Heart Health Supplement
Description: This is a natural heart health supplement in powdered format, chocolate flavor where participants will take a daily dose.
Study NCT06673251 — intervention group
Intervention type: OTHER
Intervention: motor and sensory assessments, surveys
Description: It does not include any intervention. Only evaluation will be made.
Study NCT06421246 — intervention group
Intervention type: BEHAVIORAL
Intervention: Staff-facing screen
Description: Activity will be monitored before and after the introduction of a staff-facing screen
Study NCT06039917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI based automatic surveillance (AS) system (ENDOANGEL-AS)
Description: An automatic surveillance (AS) system accurately identify patients with gastric premalignant lesions, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.
Study NCT05652764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orem's Self-Care Deficit Theory Based Nursing Interventions for Immunotherapy Treated Cancer Patients
Description: In this study, face-to-face patient education, giving patient education booklet, preparation of symptom management card, face-to-face and telephone counseling initiatives were planned to the experimental group.
Study NCT06039917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manually remind the patients
Description: Medical staff remind patients to review manually.
Study NCT05774691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protamine sulfate
Description: Routine protamine administration in a ratio of 1 mg per 100 IU of unfractionated heparin
Study NCT05774691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protamine sulfate
Description: Selective protamine administration, in case of (threatening) bleeding
Study NCT05664685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized bismuth quadruple therapy
Description: Scheme that have high dosage of amoxicillin, metronidazole and omeprazole, with bismuth. The rationale of this scheme is that in Chile, amoxicillin resistance is low, clinical metronidazole is low in the doses used and the high doses ob Proton Pump Inhibitor enhanced the antimicrobial drugs
Study NCT06526208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MB-IMP
Description: MB-IMP is a marijuana-based investigational medical product. It contains a 23:1 ratio of CBD to THC, is an oil-based tincture that is taken orally.
Study NCT06526208 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Does not contain CBD or THC
Study NCT06367062 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: MRI is used to assess of brain development.
Study NCT06276153 — intervention group
Intervention type: OTHER
Intervention: no interventions
Description: retrospective registry cohort with no other specific interventions
Study NCT06010121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liposomal Vitamin D
Description: 2000 IU of cholecalciferol in liposomal formulation
Study NCT06010121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Vitamin D
Description: 2000 IU of cholecalciferol in traditional formulation
Study NCT05664685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard eradication therapy using omeprazole, clarithromycin and amoxicillin
Study NCT05768295 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Axiom BL X3
Description: collecting data on the use of Axiom BL X3 and patient satisfaction
Study NCT03630081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 4282 (FEP-TAZ) 4 g
Description: WCK 4282 (FEP-TAZ) 4 g \[2 g FEP and 2 g TAZ\] IV q8h, infused over 90 min
Study NCT03630081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: 1 g IV q8h, infused over 45 min
Study NCT03630081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciprofloxacin 500 mg Optional Oral Switch
Description: ciprofloxacin 500 mg PO q12h
Study NCT03630081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin 500 mg Optional Oral Switch
Description: ciprofloxacin 500 mg PO q12h
Study NCT03630081 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of normal saline
Description: Infusion of normal saline over 45 min
Study NCT05528887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CAR-T cells
Description: D0: CAR-T cells will be infused intravenously.
Study NCT05528887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: D-5 to D-3: Fludarabine (30 mg/m\^2/day) will be administered intravenously for 3 days.
Study NCT05528887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: D-5 to D-3: Cyclophosphamide (500 mg/m\^2/day) will be administered intravenously for 3 days.
Study NCT05804864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KM501
Description: 1a: The program evaluated six dose levels, i.e., 0.1, 0.3, 0.6, 1.2, 1.8, 2.4 mg/kg, An accelerated titration was performed in the 0.1 and 0.3 mg/kg dose groups, and then a Bayesian optimal interval design was used to determine MTDS for four subsequent dose levels. Ib: The antitumor activity of KM501 monotherapy in subjects with specific types of tumors that are HER2-positive or express, amplify, or mutate will be evaluated at the RP2D dose level
Study NCT04346394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine HCl
Description: Yohimbine hydrochloride will be used to manipulate the noradrenergic system during some of the assessments. By measuring the amounts of hormones the body produces before and after yohimbine hydrochloride administration, researchers can assess how well the noradrenergic system is functioning